Table 5.
Outcome (OS, PFS, RR, DCR) to gefitinib therapy per mutation status and technique (N=62)
| Methods | Mutation status | Total no. pts* | OS (month) | PFS (month) | ORR** (n, %) | P-value | DCR*** (n, %) | P-value |
|---|---|---|---|---|---|---|---|---|
| DNA sequencing | Exon 19 all deletions | Mt (n=18) | 38.6 | 12.1 | 8 (44) | 16 (89) | ||
| E746-A750 | Mt (n=11) | 40.8 | 39.8 | 4 (36) | 10 (91) | |||
| L858R (including 2573 T>K) | Mt (n=11) | 34.4 | 19.9 | 4 (36) | 10 (91) | |||
| Exon 18 | Mt (n=1) | 78 | 1 (100) | 1 (100) | ||||
| Exon 20 | Mt (n=15) | 25 | 23.5 | 2 (13) | 14 (78) | |||
| EGFR WT | Wt (n=25) | 12.9 | 7.3 | 1 (4) | 0.009 | 16 (64) | 0.057 | |
| Specific mutation IHC | E746-A750 | Mt (n=9) | 22.6 | 11.6 | 2 (22) | 8 (89) | ||
| Wt (n=53) | 22.1 | 11.6 | 13 (25) | 0.882 | 41 (78) | 0.691 | ||
| L858R | Mt (n=9) | 37.8 | 19.9 | 3 (33) | 8 (89) | |||
| Wt (n=53) | 16.8 | 9.2 | 12 (23) | 0.488 | 42 (79) | 0.499 | ||
| E746-A750 & L858R | Mt (n=18) | 34.4 | 19.9 | 5 (28) | 16 (89) | |||
| Wt (n=44) | 15.7 | 8.9 | 10 (23) | 0.673 | 33 (75) | 0.227 |
*
Patients with mutation
**
ORR: Responder= CR+PR
***
Disease control rate; CR+PR+SD ≥ 12 weeks
P values are between EGFR WT and each of the mutated subtype per section.